NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 23.53% | 50.68% | 21.76% | -133.81% | 13.70% |
| Total Depreciation and Amortization | -46.93% | 1,391.67% | -76.00% | -47.37% | -37.91% |
| Total Amortization of Deferred Charges | -53.38% | -25.06% | -27.32% | -13.75% | 44.86% |
| Total Other Non-Cash Items | -92.33% | -69.85% | -63.88% | 252.41% | 183.33% |
| Change in Net Operating Assets | -583.04% | 303.51% | -89.39% | 579.46% | 83.55% |
| Cash from Operations | -256.57% | 67.49% | -466.24% | 13.74% | 80.25% |
| Capital Expenditure | 0.00% | 0.00% | 0.00% | -100.00% | 50.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -100.19% | 53,500.00% | -100.00% | 50.00% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -27.01% | -7.61% | 17.90% | -22.01% | -198.96% |
| Issuance of Common Stock | 1,173.89% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -405.26% | -116.81% | -- | 100.00% |
| Cash from Financing | 524.59% | 17.59% | -2,196.15% | 95.49% | -122.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -1,631.25% |
| Net Change in Cash | 102.43% | 17.98% | -282.16% | 71.94% | -286.96% |
